SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-19. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
=== Water softener === The reduction of water hardness in laundry applications and the dissolution of scale in boilers both rely on EDTA and related complexants to bind Ca2+, Mg2+, as well as other metal ions. Once bound to EDTA, these metal complexes are less likely to form precipitates or to interfere with the action of the soaps and detergents. For similar reasons, cleaning solutions often contain EDTA. In a similar manner EDTA is used in the cement industry for the determination of free lime and free magnesia in cement and clinkers. The solvation of Fe3+ ions at or below near neutral pH can be accomplished using EDTA. This property is useful in agriculture including hydroponics. However, given the pH dependence of ligand formation, EDTA is not helpful for improving iron solubility in above neutral soils. Otherwise, at near-neutral pH and above, iron(III) forms insoluble salts, which are less bioavailable to susceptible plant species.
The earliest description of solid carbon dioxide (dry ice) was given by the French inventor Adrien-Jean-Pierre Thilorier, who in 1835 opened a pressurized container of liquid carbon dioxide, only to find that the cooling produced by the rapid evaporation of the liquid yielded a "snow" of solid CO2. Carbon dioxide in combination with nitrogen was known from earlier times as Blackdamp, stythe or choke damp. Along with the other types of damp it was encountered in mining operations and well sinking. Slow oxidation of coal and biological processes replaced the oxygen to create a suffocating mixture of nitrogen and carbon dioxide.
Kombucha is promoted with many claims for health benefits, from alleviating hemorrhoids to combating cancer. Although people may drink kombucha for such supposed health effects (attributed first to the protective impact of tea itself, and to fermentation products including glucuronic acid, acetic acid, polyphenols, phenols, and B-complex vitamins such as folic acid), there is no clinical proof that it provides any benefit. A review found only one human study on kombucha. Kombucha is an "extreme example" of an unconventional remedy because of the disparity between implausible, wide-ranging health claims and the potential risks of the product. It concluded that the proposed, unsubstantiated therapeutic claims did not outweigh known risks, and that kombucha should not be recommended for therapeutic use, being in a class of "remedies that only seem to benefit those who sell them".
== Research == Antibodies and antigens, produced in the Human Protein Atlas workflow, are used in research projects to study potential biomarkers in various diseases, such as breast cancer, prostate cancer, colon cancer, diabetes, autoimmune diseases, ovarian cancer and renal failure. Researchers involved with Human Protein Atlas projects, are sharing protocols and method details in an open-access group on protocols.io. A large effort is put into validating the antibody reagents used for profiling of tissues and cells, and the HPA has implemented stringent antibody validation criteria as suggested by the International Working Group for Antibody Validation (IWGAV).
Sources: en.wikipedia.org
== Fort Montgomery chain (1776–1777) == In 1776 a chain and boom were stretched across the river from Fort Montgomery on the west bank, at the lower entrance to the Highlands just north of the modern-day Bear Mountain Bridge, to Anthony's Nose on the east bank. Captain Thomas Machin headed the chain effort. In November 1776, a faulty link broke under stress induced by the river current, highlighting some of the difficulties of trying to chain the Hudson. It was repaired and reset. After the British captured forts Montgomery and Clinton, a second fortress built opposite it at the mouth of Popolopen's Kill (today's Popolopen Creek) on its south bank, on October 6, 1777, they dismantled the chain. Free to do so, they raided upriver as far as Kingston, then the capitol of New York State, putting the torch to it and burning all but several of its hundreds of buildings to the ground. Governor George Clinton, a member of the committee assigned by the New York Convention to devise a means of defending the Hudson, was heartened as the British had never attempted to run ships through the chain. He concluded that the basic idea of obstructing the river seemed sound. After Captain Machin recovered from wounds from battle with the British, he began work on the stronger Great Chain at West Point, which was constructed and installed in 1778.
====== Medication assisted treatment (MAT): Opioid agonist therapy (OAT) and Opioid substitution therapy (OST) ====== Medication assisted treatment (MAT) is the prescription of legal, prescribed opioids or other drugs, often long-acting, to diminish the use of illegal opioids. Many types of MAT exist, including opioid agonist therapy (OAT) where a safer opioid agonist is employed or opioid substitution therapy (OST) which employs partial opioid agonists. However, MAT, OAT, OST are often used synonymously. Opioid agonist therapy (OAT) involves the use of a full opioid agonist treatment like methadone and is generally taken daily at a clinic. Opioid substitution therapy (OST) involves the use of the partial agonist buprenorphine or a combination of buprenorphine/naloxone (brand name Suboxone). Oral/sublingual formulations of buprenorphine incorporate the opioid antagonist naloxone to prevent people from crushing the tablets and injecting them. Unlike methadone treatment, buprenorphine therapy can be prescribed month-to-month and obtained at a traditional pharmacy rather than a clinic. The driving principle behind OAT/OST is the program's capacity to facilitate a resumption of stability in the person's life, while they experience reduced symptoms of withdrawal symptoms and less intense drug cravings; however, a strong euphoric effect is not experienced as a result of the treatment drug. In some countries, such as Switzerland, Austria, and Slovenia, patients are treated with slow-release morphine when methadone is deemed inappropriate due to the individual's circumstances.
The Hamley group have also carried out investigations of palmitoyl-KTTKS, and found it so self-assemble into nano tapes in the pH range 3–7, in addition to stimulating human dermal and corneal fibroblasts in a concentration dependant manner, suggesting that stimulation occurs above the critical aggregation concentration. There exist some rarer forms of protein acylation that may not have a membrane-related function. They include serine O-octanoylation in ghrelin, serine O-palmitoleoylation in Wnt proteins, and O-palmitoylation in histone H4 with LPCAT1. Hedgehog proteins are double-modified by (N-)palmitate and cholesterol. Some skin ceramides are proteolipids. The amino group on lysine can also be myristoylation via a poorly-understood mechanism.
== As a drug target == The oxoglutarate dehydrogenase complex (α-ketoglutarate dehydrogenase complex) is responsible for converting AKG into succinyl-CoA in the citric acid cycle. It is one of the rate-limiting enzymes in the cycle. In breast cancer with lung metasatsis models, inhibiting this enzyme (causing an accumulation of AKG) reduces cancer cell growth; a similar effect is observed with AKG supplementation in mice with B-cell lymphoma. On the other hand, a dysfunction of this enzyme (again causing AKG accumulation) leads to increased lipid peroxidation in CHCHD2-linked Parkinson's disease models and appears to be partly responsible for elevated phosphorylated α-synuclein levels, as improving the function of this complex causes both AKG and phosphorylated α-synuclei to decrease.
Like the world, the EU's greatest task is to replace fossil fuels with clean energy as fast as technology allows since protection of "life", and "improvement of the quality of the environment" are fundamental rights, and the highest policy goals of the EU. In international law, there is also 'the inherent right of all peoples to enjoy and utilize fully and freely their natural wealth and resources' such as clean air, and the right to 'the benefits of scientific progress', such as clean energy. The EU's overall target is to reduce toxic greenhouse gas emissions by 50–55% by 2030, and be carbon neutral or negative by 2050, and 32% renewable energy by 2030, though a 45% target by 2030 was proposed by the commission and backed by Parliament in 2022. Since the 2022 Russian invasion of Ukraine it aims to eliminate Russian fossil fuel imports as fast as possible. However laws such as the Hydrocarbons Directive 1994 still enable gas and oil extraction. It requires that licences are awarded based on technical and financial capability, methods, price, and previous conduct, that applicants are treated equally by objective and non-discriminatory criteria, and advertisements for tenders must be public. It has not yet required that existing licensees pay for the pollution and climate damage they have caused, nor sought to end extraction of gas and oil.
Sources: en.wikipedia.org
In periodontology, gingival grafting, also called gum grafting or periodontal plastic surgery, is a generic term for the performance of any of a number of surgical procedures in which the gingiva (gum tissue) is grafted. The aim may be to cover exposed root surfaces or merely to augment the band of keratinized tissue.
Drew insisted that there was no racial difference in human blood and that the policy would lead to needless deaths as soldiers and sailors were required to wait for "same race" blood. By the end of the war the American Red Cross had provided enough blood for over six million plasma packages. Most of the surplus plasma was returned to the United States for civilian use. Serum albumin replaced dried plasma for combat use during the Korean War.
Stave (1959), historian specializing in oral history and urban history Alvin Goldman (1960), professor of philosophy at Rutgers University and leading figure in epistemology William Landes (1960), economist and professor at University of Chicago Law School Rudolf Makkreel (1960), professor of philosophy at Emory University Thomas Vargish (1960), professor of English at Dartmouth College Eugene Bardach (1961), public policy scholar, professor at University of California, Berkeley Marshall Berman (1961), urbanologist Martin Eidelberg (1961), art historian at Rutgers University David Konstan (1961), professor of classics at New York University Victor Hao Li (1961), professor at Stanford Law School, president of East–West Center 1981–1989 Donald F. Roberts (1961), professor of communications at Stanford University David Syrett (1961), professor of military history at Queens College, City University of New York; former president of the New York Military Affairs Symposium Zvi Gitelman (1962), Jewish scholar at the University of Michigan Ken Jowitt (1962), political scientist and professor at University of California, Berkeley and senior fellow of the Hoover Institution Stephen Koss (1962), historian on British history Joel Moses (1962), mathematician, Institute Professor at and provost of the Massachusetts Institute of Technology Lawrence S.
The Orange Book, formally titled Compendium of Analytical Nomenclature, contains internationally accepted definitions for terms in analytical chemistry. It has traditionally been published in an orange cover. Although the book is described as the "Definitive Rules", there have been three editions published; the first in 1978 (ISBN 0-08022-008-8), the second in 1987 (ISBN 0-63201-907-7) and the third in 1998 (ISBN 0-86542-615-5). The third edition is also available online. A Catalan translation has also been published (1987, ISBN 84-7283-121-3).
Efficient oxidation reactions of precursors of important basic chemicals are of particular technical interest. For example, ε-caprolactam can be prepared using NHPI from the so-called KA oil ("ketone-alcohol" oil, a mixture of cyclohexanol and cyclohexanone) which is obtained during the oxidation of cyclohexane. The reaction proceeds via cyclohexanol hydroperoxide, which reacts with ammonia to give peroxydicyclohexylamine followed by a rearrangement in the presence of catalytic amounts of lithium chloride.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.